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Abstract:
There is a predominance of small and dense LDL cholesterol particles in familial
combined hyperlipidemia (FCH). The lipoprotein lipase gene could exert an influence
in these circumstances.
To study the relationship of pattern B LDL and lipids with N291S polymorphism of
lipoprotein lipase (LPL) in FCH patients.
Lipid profile, apolipoproteins, diameter of LDL and N291S polymorphism were
determined in 93 patients with FCH and 286 individuals from the general population.
FCH patients with N291S polymorphism showed a lower mean diameter of LDL. FCH
patients with pattern B LDL showed higher concentrations of triglycerides, VLDLc,
non-HDLc and apo B100 and lower levels of HDLc than those with pattern A. Of FCH
patients with polymorphism 87.5% presented pattern B and 12.5% pattern A, while
patients without polymorphism presented pattern A in 69.2% cases and pattern B in
30.8% cases, with differences being statistically significant (p< 0.004). The prevalence
of this mutation in our FCH patients was 9.7 %.
The prevalence of N291S mutation in our FCH patients was similar to the 9.3%
described in Dutch FCHL patients but clearly higher than the 2-5% described for other
Caucasian populations. No polymorphism was found in our general population sample.
FCH patients with phenotype B of LDL possessed an atherogenic lipid profile. The
relationship between small and dense LDL and the presence of the N291S mutation may
identify patients with high cardiovascular risk.
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Background
A common form of dyslipemia associated with insulin resistance (obesity, diabetes
mellitus, familial combined hyperlipidemia) is constituted by the presence of the
atherogenic lipoprotein phenotype, characterized by elevated levels of triglycerides,
small LDL particles and reduced HDL cholesterol [1]. This lipid triad frequently occurs
in patients with premature coronary disease [2]. Small and dense LDL particles are
formed largely as a response to high levels of triglycerides, and increase the risk of
coronary heart disease [3]. LDL particles show a bimodal distribution in peak size and
can be separated into two phenotypes; pattern A, in which larger, more buoyant LDL
predominate, and pattern B, in which smaller, more dense LDL predominate. The
National Cholesterol Education Program (ATP III) considers small and dense LDL as a
lipid risk factor.
Familial Combined Hyperlipidemia (FCH; MIM 144250) is the most frequent
genetic hyperlipemia. It is characterized by a tendency towards the appearance of
coronary disease before 60 years of age [4]. The prevalence of this disease is 1-2% in
the general population [5] and 10-20% among patients with premature coronary disease
[6]. FCH presents a complex phenotype that is not completely understood, and which
can vary between the patient and affected relatives [7]. Therefore, it is difficult to
diagnose. It is also characterized by the presence of the atherogenic lipoprotein
phenotype and an increase in apolipoprotein B100 [8].
Several genes have been studied in relation with FCH, which is a polygenic
disease. One of the genes involved in FCH is lipoprotein lipase (LPL, E.C. 3.1.1.34) [9],
a glycoproteic enzyme that plays a key role in the catabolism of lipoproteins rich in
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triglycerides, such as chylomicrons, and very low density lipoproteins (VLDL). LPL
action takes place in endothelial cells surrounding the lumen of capillary vessels, where
it adheres to heparan sulphate proteoglycans [10].
More than 80 structural mutations have been detected within the LPL gene. The
frequency of these mutations in the general population is estimated to be at least 1/500.
These heterozygous mutations are the main cause of some lipid disorders. One of these
mutations is N291S localized in exon 6 of LPL [11-13].
The aim of our study was to analyze the relationship of the atherogenic lipoprotein
profile, especially the predominance of small and dense LDL, with the prevalence of
N291S LPL polymorphism in Spanish patients with FCH from the Community of
Valencia with respect to with the general population.
Material and methods
Our study sample consisted of 33 families with Familial Combined Hyperlipidemia
(FCH), with a mean of 4.4 individuals per family, all of them living in the Autonomous
Community of Valencia (SE of Spain). From a total of 146 subjects, 93 were diagnosed
with FCH according to the criteria of Bredie SJ et al. [14]. Total cholesterol and
triglycerides levels superior to the 90th percentile (adjusted to age and gender) and apo
B100 values superior to 1.2g/L represented a diagnosis of FCH in 43 men and 50
women, aged from 15 to 75 years. In order to assess polymorphism in the general
population, 286 genetically independent healthy controls of similar gender and age were
randomly selected.
Venous blood was collected for biochemical measurements. Total cholesterol (TC) and
triglycerides (TG) were measured through enzymatic methods and high density
lipoproteins cholesterol (HDLc) using a direct method in a Beckman LX20 auto
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analyzer. The intraserial variation coefficient was < 3.5% for all these determinations.
When TG values were under 400 mg/dL, LDL cholesterol concentration was calculated
using Friedewald´s formule [15]. Non-HDL cholesterol was obtained from the
difference between total cholesterol and HDL cholesterol. Apolipoproteins AI and
B100 were determined by immunonephelometry in a Dade Behring BNII (intra-assay
variation coefficient < 5.5%).
LDL B phenotype was measured by polyacrylamide gradient gel electrophoresis (2-
16%) using the methodology described by Nichols et al. [16]. The assignment of LDL
subclass phenotypes was based on particle diameter: pattern A, mean diameter > 25.5
nm, and pattern B, predominance of small and dense particles with a mean diameter ≤
25.5 nm [17].
Approval was obtained from the relevant institutional review board, and all participants
gave their informed consent.
DNA analysis for RFLP detection in LPL
DNA was extracted from tubes of 15 mL of blood with EDTA-K3, according to the
method of Miller et al. [18], and was conserved at 4º C until analysis was performed.
N291S was identified after PCR amplification of a 238 bp fragment using the following
oligonucleotides: forward 5´ GCCGAGATACAATCTTGGTG 3´ and reverse 5´
CTGCTTCTTTTGGCTCTGACTGT 3´. Such a polymorphism adds a restriction site
for the Ava II enzyme. PCR reaction was performed in 25 µl total volume containing
0.3 mM of each primer, 0.2 mM of each dNTP, 1x Taq buffer, 2 mM MgCl2, 100 ng of
genomic DNA and 2.5 U Taq polymerase (Netzyme) in a Master-Cycler thermocycler
(Eppendorf). PCR was performed by means of a touchdown protocol [19] according to
the following conditions: an initial denaturation step of 10 minutes at 94º C was
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followed by 4 cycles of 30 seconds at 94º C, 30 seconds at 60º C and 45 seconds at 72º
C. This was followed by 20 cycles of 30 seconds at 94º C, 30 seconds at 60º C minus
0.5ºC in each cycle and 45 seconds at 72º C, and then 10 cycles of 30 seconds at 94º C,
30 seconds at 50º C and 45 seconds at 72º C. The final extension consisted of 10
minutes at 72º C. The PCR product was digested for 4 hours at 37º C with Ava II and
then analyzed with an 8% polyacrylamide gel. If the polymorphism was present, two
fragments of 215 and 23 bp (HT+) appeared; if not, the site was destructed in the
normal chain, which remained non-digested (238 bp: WT).
Study design
The study was conducted based on a case-control design. Ninety-three FCHL patients
were recruited and matched according to sex and age with a control group of 286
subjects from the general population.
Statistics
Between-groups comparison was performed using an ANOVA followed by a
parametric t-test. Due to skewed distribution of TG, TG analyses were performed on
logarithmically transformed values. Statistical analyses were carried out using the
Microsoft Excel Data Analysis Package (Microsoft, Inc.).
The Mann-Whitney nonparametric test was used to compare lipid concentrations in
FCH patients with pattern A and those with pattern B. To test differences in
triglycerides levels, values were logarithmically transformed prior to statistical analysis.
χ 2 was performed in order to determine whether populations were in Hardy-Weinberg
equilibrium and in order to compare different phenotypes. Significance was set at p <
0.05.
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Statistic analyses were carried out using the SSPS-15.0 program for Windows (SPSS
Inc., Chicago, IL).
Results
A total of 93 patients, all diagnosed with FCH, were studied: 43 men (46.3%) and 50
women (53.7%), aged between 15 and 75. 286 subjects from the general population
were also studied. Lipid parameters are expressed in Table 1. Significant differences
were observed between the two groups in all the variables studied. FCH patients
showed higher levels of total cholesterol, triglycerides, LDLc, non-HDLc and apo
B100, and lower levels of HDLc, apo A and a smaller LDL diameter.
When non-mutated wild-type (WT) and heterozygote (HT) patients were compared, a
smaller average diameter of LDL particles was observed among the latter, with the
difference being statistically significant. Table 2 shows the lipid values of pattern A
patients compared to those of pattern B patients. FCH patients with pattern B LDL
displayed higher concentrations of triglycerides, VLDLc, non-HDLc and apo B100 and
lower levels of HDLc than FCH patients with pattern A.
Patients with polymorphism presented pattern B in 87.5% of cases and pattern A in
12.5% of cases, while patients without polymorphism presented pattern A in 69.2% of
cases and pattern B in 30.8% of cases. These differences were statistically significant
(p< 0.004).
N291S polymorphism of LPL occurred in 9.7% of FCH patients, while no individual in
the study sample from the general population presented this mutation. Both samples
were in Hardy-Weinberg equilibrium, as the patients showed a χ2=0.216 and 2p=
0.6423 and the general population a χ2=0 and 2p=1.
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Discussion
FCH is a disease with a complex phenotype that is not completely understood, and
remains difficult to diagnose. This dyslipemic syndrome is associated with disturbances
in all lipoprotein fractions. The key underlying abnormality of this condition is
elevation of VLDL due to overproduction or defective catabolism [20]. Small and dense
LDL is the final expression of this catabolism. These particles are more easily oxidized
and display a higher affinity for the extracellular matrix and a higher degree of retention
in arterial wall than their larger, normal-sized counterparts [21]. Small and dense LDL
has been accepted as an emergent cardiovascular risk factor by the National Cholesterol
Education Programme (Adult Treatment Panel III) [22], as many studies have
demonstrated that the predominance of these particles is associated with an increase in
cardiovascular risk more than classic lipid variables [23, 24]. FCH patients with
phenotype B of LDL show a clearly atherogenic lipid profile. There is evidence that
hypolipidemic treatment can modify the distribution of LDL subclasses [25]. Very high
risk patients, including those with this atherogenic lipoprotein profile, may benefit from
more potent lipid-lowering therapies [26].
It has been suggested that FCH is a heterogeneous and oligogenic disease [27].
One of the genes likely to exert an influence in this disease is the lipoprotein lipase
gene. Many codon polymorphisms of the LPL gene have been described, some of them
associated with alterations of the metabolism of triglyceride-rich lipoproteins [28]. One
of the most frequent polymorphisms is located in exon 6 (rs268, c. 1128 A>G; N291S)
[29]. The prevalence of this mutation in our FCH patients was 9.7 %, which is similar to
the 9.3% described for Dutch FCH patients [5] but considerably higher than the 2-5%
described for other Caucasian populations [30]. No polymorphism was detected in the
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sample from the general population, which reflects findings in other populations [5] in
which no carriers were found, suggesting that the N291S mutation is more frequent
among FCH patients. The mutation is likely to affect postprandial lipemia by altering its
enzymatic activity [31], resulting in an increase of VLDL particles and high
concentrations of apo B100 and leading to the appearance of a greater number of small
and dense LDL particles as the final and most important expression of the catabolism of
triglyceride-rich lipoprotein particles [32]. In this way, the FCH phenotype of patients
with the polymorphism is negatively affected, with altered postprandial responses to fat-
rich meals being described, even in patients that were initially normolipemic [33].
These previously published data coincide with our results; polymorphism-carrier
patients have been reported to present a smaller LDL diameter, suggesting a clearly
atherogenic alteration of the metabolism of triglyceride-rich particles [34]. In fact, in
some studies regarding FCH, this polymorphism has been related to patients who had
previously presented an ischemic cardiopathy [11].
In our study, patients with the N291S polymorphism showed a smaller average LDL
diameter, corresponding with pattern B and constituting the final expression of the
alteration of the metabolism of triglyceride-rich particles. This represents a higher
cardiovascular risk among such patients. On the other hand, most patients without this
polymorphism had pattern A, constituting a clear difference between both groups. We
are aware of the limitations of this study in relation to the number of patients with the
polymorphism. Unfortunately, its low prevalence among the general population makes
it difficult to conduct a genetic study with a large number of patients that would permit
us to draw more solid conclusions. That said, our data show important differences
between the two patterns.
In conclusion, FCH patients with pattern B of LDL show a clearly atherogenic lipid
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profile. The relationship between small and dense LDL and the presence of the allele
encoding for N291S mutation of the LPL gene, present in a high percentage of our FCH
patients, could disrupt the phenotype of the disease by altering the clearance of
triglyceride-rich lipoproteins. Such phenotype expression is the basis for a more
atherogenic profile. Therefore, based on our results in FCH patients in the Autonomous
Community of Valencia, the cardiovascular risk of those with pattern B of LDL who
carry this polymorphism could be considerably reduced through rigorous treatment of
Hyperlipemia.
Abbreviations
FCH: Familial combined hypermipidemia, LPL: lipoprotein lipase, WT: non-mutated
wil-type, HT: Heterzygote.
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Table 1. Lipid concentrations in cases (FCH patients) and controls.
FCH Patients Controls P value*
Total cholesterol 238.67±50.10 185.13±28.30 0.001
Triglycerides 204.71±192.16 88.27±42.45 0.001
LDLc 156.85±39.97 113.50±25.20 0.001
HDLc 47.77±17.18 53.93±14.48 0.001
VLDLc 40.28±36.52 17.65±8.49 0.001
Non-HDLc 192.94±48.68 131.50±29.09 0.001
Apo AI 133.55±32.52 152.79±29.03 0.001
Apo B100 125.80±28.11 95.25±21.15 0.001
LDL diameter 25.45±0.78 26.14±0.74 0.001
* ANOVA Test
Values are expressed as mean ± standard deviation. Units are mg/dL in all parameters
except LDL diameter (nm).
 17
Table 2. Lipid concentrations in FCH patients with pattern A and pattern B
Pattern A (n=26) Pattern B (n=27) P-value*
Total cholesterol 227.88±41.86 238.03±50.86 0.450
Triglycerides 127.80±65.77 344.55±234.40 0.001
HDLc 55.00±18.54 35.59±7.94 0.001
LDLc 147.50±34.64 149.06±53.11 0.569
VLDLc 25.53±13.11 65.34±43.71 0.001
Non-HDLc 172.88±32.40 202.44±50.71 0.022
Apo AI 144.00±39.87 121.33±20.49 0.029
Apo B100 118.13±22.22 133.69±30.21 0.042
ApoB/ApoA 0.90±0.29 1.50±0.35 0.022
Diameter 26.06±0.57 24.86±0.42 0.001
* Mann-Whitney test
Values expressed as mean ± Standard Deviation. Units are mg/dL in all parameters
